Arcus Biosciences Dividend

Dividend criteria checks 0/6

Arcus Biosciences does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$3.38
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Mar 20

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Feb 23

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Feb 22

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Dec 18

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Aug 08

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Jun 15

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

May 05

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Nov 02

Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers

May 12

Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add

Jan 07

Forecast: Analysts Think Arcus Biosciences, Inc.'s (NYSE:RCUS) Business Prospects Have Improved Drastically

Nov 25

Analysts Just Shaved Their Arcus Biosciences, Inc. (NYSE:RCUS) Forecasts Dramatically

Aug 08

Need To Know: Analysts Are Much More Bullish On Arcus Biosciences, Inc. (NYSE:RCUS) Revenues

Jun 26

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if RCUS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RCUS's dividend payments have been increasing.

Dividend Yield vs Market

Arcus Biosciences Dividend Yield vs Market

How does RCUS dividend yield compare to the market?
Segment	Dividend Yield
Company (RCUS)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Biotechs)	2.9%
Analyst forecast in 3 Years (RCUS)	0%

Notable Dividend: Unable to evaluate RCUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RCUS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate RCUS's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RCUS has not reported any payouts.

Arcus Biosciences Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Arcus Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer recently sold US$241k worth of stock

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Chief Operating Officer notifies of intention to sell stock

Consensus revenue estimates increase by 35%, EPS downgraded

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Price target decreased by 7.9% to US$39.70

Arcus Biosciences, Inc. Announces Data from A Phase 1B Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naive Metastatic Pancreatic Cancer

Co-Founder notifies of intention to sell stock

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Co-Founder notifies of intention to sell stock

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Arcus Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Insufficient new directors

COO & Director notifies of intention to sell stock

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcus Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023

New minor risk - Shareholder dilution

Arcus Biosciences, Inc. announced that it expects to receive $19.4526 million in funding from Gilead Sciences, Inc.

COO & Director notifies of intention to sell stock

COO & Director recently sold US$243k worth of stock

COO & Director notifies of intention to sell stock

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Arcus Biosciences, Inc. Provides Updated Results from an Interim Analysis of ARC-7

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

COO & Director recently sold US$147k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023

COO & Director notifies of intention to sell stock

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces Positive Results for the Fourth Interim Analysis of the ARC-7 Study in Patients

COO & Director recently sold US$507k worth of stock

Investor sentiment improved over the past week

Arcus Biosciences, Inc. Announces Positive Update from the Fourth Interim Analysis of ARC-7

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Arcus Biosciences, Inc. to Report Q3, 2022 Results on Nov 02, 2022

COO & Director recently sold US$333k worth of stock

Price target decreased to US$50.10

Arcus Biosciences, Inc. Appoints Dimitry S.A. Nuyten as Chief Medical Officer

Price target decreased to US$50.80

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Arcus Biosciences, Inc. to Report Q2, 2022 Results on Aug 03, 2022

COO & Director recently sold US$272k worth of stock

Investor sentiment improved over the past week

Consensus revenue estimates fall by 18%

Price target decreased to US$59.70

Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

Arcus Biosciences, Inc., Annual General Meeting, Jun 14, 2022

Consensus forecasts updated

Investor sentiment deteriorated over the past week

Consensus revenue estimates fall by 24%

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Arcus Biosciences, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones

Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add

COO & Director notifies of intention to sell stock

Forecast: Analysts Think Arcus Biosciences, Inc.'s (NYSE:RCUS) Business Prospects Have Improved Drastically